Price T Rowe Associates Inc Lyell Immunopharma, Inc. Transaction History

Price T Rowe Associates Inc

$867 Billion
Q4 2024

A detailed history of Price T Rowe Associates Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,910,749 shares of LYEL stock, worth $4.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,910,749

Previous 7,352,277 6.01%

Holding current value

$4.22 Million

Previous $10.1 Million 56.4%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.59 - $1.48 $260,501 - $653,461	-441,528 Reduced 6.01%	6,910,749 $4.42 Million
Q3 2024 Nov 14, 2024	SELL	$1.13 - $1.88 $587,703 - $977,772	-520,092 Reduced 6.61%	7,352,277 $10.1 Million
Q2 2024 Aug 14, 2024	BUY	$1.3 - $3.01 $1.48 Million - $3.43 Million	1,140,892 Added 16.95%	7,872,369 $11.4 Million
Q1 2024 May 15, 2024	BUY	$1.71 - $3.07 $158,335 - $284,263	92,594 Added 1.39%	6,731,477 $15 Million
Q4 2023 Feb 14, 2024	SELL	$1.39 - $2.35 $65,766 - $111,187	-47,314 Reduced 0.71%	6,638,883 $12.9 Million
Q3 2023 Nov 14, 2023	SELL	$1.45 - $3.35 $2.14 Million - $4.94 Million	-1,474,897 Reduced 18.07%	6,686,197 $9.83 Million
Q2 2023 Aug 14, 2023	BUY	$1.89 - $3.86 $7.93 Million - $16.2 Million	4,193,756 Added 105.71%	8,161,094 $26 Million
Q1 2023 May 15, 2023	BUY	$1.97 - $3.58 $574,554 - $1.04 Million	291,652 Added 7.93%	3,967,338 $9.36 Million
Q4 2022 Feb 14, 2023	SELL	$2.78 - $8.09 $4.53 Million - $13.2 Million	-1,630,921 Reduced 30.73%	3,675,686 $12.8 Million
Q3 2022 Nov 14, 2022	SELL	$5.54 - $8.27 $115,725 - $172,752	-20,889 Reduced 0.39%	5,306,607 $38.9 Million
Q2 2022 Aug 15, 2022	SELL	$3.68 - $6.8 $612,447 - $1.13 Million	-166,426 Reduced 3.03%	5,327,496 $34.7 Million
Q1 2022 May 16, 2022	BUY	$5.05 - $7.7 $1.78 Million - $2.72 Million	352,631 Added 6.86%	5,493,922 $27.7 Million
Q4 2021 Feb 14, 2022	BUY	$7.13 - $15.19 $10.6 Million - $22.5 Million	1,482,021 Added 40.5%	5,141,291 $39.8 Million
Q3 2021 Nov 15, 2021	BUY	$11.0 - $17.95 $12.8 Million - $20.8 Million	1,159,270 Added 46.37%	3,659,270 $54.2 Million
Q2 2021 Aug 16, 2021	BUY	$15.99 - $16.89 $40 Million - $42.2 Million	2,500,000 New	2,500,000 $40.6 Million

Others Institutions Holding LYEL

# of Institutions

109

Shares Held

163M

Call Options Held

18.1K

Put Options Held

200

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Lyell Immunopharma, Inc. Transaction History